Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

114 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Novel peptide-based oncolytic vaccine for enhancement of adaptive antitumor immune response via co-engagement of innate Fcγ and Fcα receptors.
Feola S, Hamdan F, Russo S, Chiaro J, Fusciello M, Feodoroff M, Antignani G, D'Alessio F, Mölsä R, Stigzelius V, Bottega P, Pesonen S, Leusen J, Grönholm M, Cerullo V. Feola S, et al. Among authors: pesonen s. J Immunother Cancer. 2024 Mar 8;12(3):e008342. doi: 10.1136/jitc-2023-008342. J Immunother Cancer. 2024. PMID: 38458776 Free PMC article.
Characterization of a novel OX40 ligand and CD40 ligand-expressing oncolytic adenovirus used in the PeptiCRAd cancer vaccine platform.
Ylösmäki E, Ylösmäki L, Fusciello M, Martins B, Ahokas P, Cojoc H, Uoti A, Feola S, Kreutzman A, Ranki T, Karbach J, Viitala T, Priha P, Jäger E, Pesonen S, Cerullo V. Ylösmäki E, et al. Among authors: pesonen s. Mol Ther Oncolytics. 2021 Feb 10;20:459-469. doi: 10.1016/j.omto.2021.02.006. eCollection 2021 Mar 26. Mol Ther Oncolytics. 2021. PMID: 33718594 Free PMC article.
Peptides-Coated Oncolytic Vaccines for Cancer Personalized Medicine.
Feola S, Russo S, Martins B, Lopes A, Vandermeulen G, Fluhler V, De Giorgi C, Fusciello M, Pesonen S, Ylösmäki E, Antignani G, Chiaro J, Hamdan F, Feodoroff M, Grönholm M, Cerullo V. Feola S, et al. Among authors: pesonen s. Front Immunol. 2022 Apr 14;13:826164. doi: 10.3389/fimmu.2022.826164. eCollection 2022. Front Immunol. 2022. PMID: 35493448 Free PMC article.
PeptiVAX: A new adaptable peptides-delivery platform for development of CTL-based, SARS-CoV-2 vaccines.
Feola S, Chiaro J, Fusciello M, Russo S, Kleino I, Ylösmäki L, Kekäläinen E, Hästbacka J, Pekkarinen PT, Ylösmäki E, Capone S, Folgori A, Raggioli A, Boni C, Tiezzi C, Vecchi A, Gelzo M, Kared H, Nardin A, Fehlings M, Barban V, Ahokas P, Viitala T, Castaldo G, Pastore L, Porter P, Pesonen S, Cerullo V. Feola S, et al. Among authors: pesonen s. Int J Biol Macromol. 2024 Mar;262(Pt 1):129926. doi: 10.1016/j.ijbiomac.2024.129926. Epub 2024 Feb 6. Int J Biol Macromol. 2024. PMID: 38331062
Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients.
Cerullo V, Pesonen S, Diaconu I, Escutenaire S, Arstila PT, Ugolini M, Nokisalmi P, Raki M, Laasonen L, Särkioja M, Rajecki M, Kangasniemi L, Guse K, Helminen A, Ahtiainen L, Ristimäki A, Räisänen-Sokolowski A, Haavisto E, Oksanen M, Karli E, Karioja-Kallio A, Holm SL, Kouri M, Joensuu T, Kanerva A, Hemminki A. Cerullo V, et al. Among authors: pesonen s. Cancer Res. 2010 Jun 1;70(11):4297-309. doi: 10.1158/0008-5472.CAN-09-3567. Epub 2010 May 18. Cancer Res. 2010. PMID: 20484030
114 results